Research has not yet evaluated whether myo-inositol can balance hormones in healthy people without PCOS or fertility issues.
Myo-inositol—typically given at 2–4 g daily in combination with 200–400 μg folic acid—has been shown to improve ovarian parameters in women with polycystic ovary syndrome. In non‐PCOS women undergoing in vitro fertilization, one study reported that myo-inositol reduced gonadotropin requirements (2,084 ± 648 IU versus 2,479 ± 979 IU, p < 0.05) and modified luteinizing hormone levels (2.7 ± 1.1 vs. 1.6 ± 0.9, p < 0.01) while yielding fewer oocytes (5.9 ± 2.4 vs. 7.6 ± 3.8, p < 0.01) and producing no significant differences in pregnancy or implantation rates. No study has evaluated hormone balancing effects in healthy, non-infertile populations outside of the assisted reproduction setting. Mild gastrointestinal side effects have been noted at higher doses, although no substantial safety concerns were reported.